nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—NISCH—mammary gland—lung cancer	0.00998	0.133	CbGeAlD
Phentolamine—NISCH—Podofilox—Teniposide—lung cancer	0.00645	0.239	CbGdCrCtD
Phentolamine—NISCH—Paclitaxel—Docetaxel—lung cancer	0.00598	0.222	CbGdCrCtD
Phentolamine—SIGMAR1—mammary gland—lung cancer	0.0058	0.0774	CbGeAlD
Phentolamine—NISCH—bronchus—lung cancer	0.00547	0.073	CbGeAlD
Phentolamine—NISCH—trachea—lung cancer	0.00491	0.0655	CbGeAlD
Phentolamine—ADRA1D—epithelium—lung cancer	0.00464	0.0619	CbGeAlD
Phentolamine—NISCH—Vincristine—Vinorelbine—lung cancer	0.00411	0.152	CbGdCrCtD
Phentolamine—NISCH—bone marrow—lung cancer	0.0039	0.052	CbGeAlD
Phentolamine—NISCH—Podofilox—Etoposide—lung cancer	0.00384	0.142	CbGdCrCtD
Phentolamine—NISCH—lung—lung cancer	0.00353	0.0471	CbGeAlD
Phentolamine—NISCH—Vinblastine—Vinorelbine—lung cancer	0.0033	0.123	CbGdCrCtD
Phentolamine—NISCH—Vincristine—Vinblastine—lung cancer	0.00328	0.122	CbGdCrCtD
Phentolamine—SIGMAR1—bronchus—lung cancer	0.00318	0.0425	CbGeAlD
Phentolamine—SIGMAR1—trachea—lung cancer	0.00286	0.0381	CbGeAlD
Phentolamine—SIGMAR1—cardiac atrium—lung cancer	0.00268	0.0358	CbGeAlD
Phentolamine—ADRA1A—epithelium—lung cancer	0.00266	0.0355	CbGeAlD
Phentolamine—ADRA2C—bronchus—lung cancer	0.0025	0.0333	CbGeAlD
Phentolamine—NISCH—lymph node—lung cancer	0.00241	0.0322	CbGeAlD
Phentolamine—SIGMAR1—bone marrow—lung cancer	0.00227	0.0302	CbGeAlD
Phentolamine—ADRA2C—trachea—lung cancer	0.00224	0.0299	CbGeAlD
Phentolamine—Angiopathy—Vinorelbine—lung cancer	0.00222	0.00309	CcSEcCtD
Phentolamine—Acute coronary syndrome—Irinotecan—lung cancer	0.00222	0.00309	CcSEcCtD
Phentolamine—Hypertension—Vinblastine—lung cancer	0.00221	0.00308	CcSEcCtD
Phentolamine—Mediastinal disorder—Vinorelbine—lung cancer	0.00221	0.00307	CcSEcCtD
Phentolamine—Myocardial infarction—Irinotecan—lung cancer	0.0022	0.00307	CcSEcCtD
Phentolamine—Nausea—Crizotinib—lung cancer	0.0022	0.00306	CcSEcCtD
Phentolamine—Arrhythmia—Vinorelbine—lung cancer	0.00219	0.00304	CcSEcCtD
Phentolamine—Abdominal pain upper—Paclitaxel—lung cancer	0.00217	0.00303	CcSEcCtD
Phentolamine—Orthostatic hypotension—Paclitaxel—lung cancer	0.00217	0.00303	CcSEcCtD
Phentolamine—Abdominal pain—Teniposide—lung cancer	0.00217	0.00302	CcSEcCtD
Phentolamine—Acute coronary syndrome—Gemcitabine—lung cancer	0.00216	0.00301	CcSEcCtD
Phentolamine—Vomiting—Pemetrexed—lung cancer	0.00215	0.003	CcSEcCtD
Phentolamine—Myocardial infarction—Gemcitabine—lung cancer	0.00215	0.00299	CcSEcCtD
Phentolamine—Vomiting—Gefitinib—lung cancer	0.00214	0.00298	CcSEcCtD
Phentolamine—Injection site pain—Doxorubicin—lung cancer	0.00212	0.00296	CcSEcCtD
Phentolamine—Chest pain—Topotecan—lung cancer	0.00212	0.00295	CcSEcCtD
Phentolamine—ADRA2C—cardiac atrium—lung cancer	0.00211	0.0281	CbGeAlD
Phentolamine—Chest pain—Erlotinib—lung cancer	0.0021	0.00292	CcSEcCtD
Phentolamine—Bradycardia—Irinotecan—lung cancer	0.00205	0.00286	CcSEcCtD
Phentolamine—SIGMAR1—lung—lung cancer	0.00205	0.0274	CbGeAlD
Phentolamine—Acute coronary syndrome—Cisplatin—lung cancer	0.00201	0.0028	CcSEcCtD
Phentolamine—Nausea—Pemetrexed—lung cancer	0.00201	0.0028	CcSEcCtD
Phentolamine—Myocardial infarction—Cisplatin—lung cancer	0.002	0.00279	CcSEcCtD
Phentolamine—Nausea—Gefitinib—lung cancer	0.002	0.00278	CcSEcCtD
Phentolamine—ADRA2A—bronchus—lung cancer	0.00199	0.0266	CbGeAlD
Phentolamine—Nervous system disorder—Topotecan—lung cancer	0.00199	0.00278	CcSEcCtD
Phentolamine—Nervous system disorder—Erlotinib—lung cancer	0.00197	0.00275	CcSEcCtD
Phentolamine—Asthenia—Teniposide—lung cancer	0.00197	0.00274	CcSEcCtD
Phentolamine—Pruritus—Teniposide—lung cancer	0.00194	0.0027	CcSEcCtD
Phentolamine—Paraesthesia—Vinblastine—lung cancer	0.00188	0.00262	CcSEcCtD
Phentolamine—Diarrhoea—Teniposide—lung cancer	0.00188	0.00261	CcSEcCtD
Phentolamine—Cardiac disorder—Irinotecan—lung cancer	0.00187	0.00261	CcSEcCtD
Phentolamine—Flushing—Irinotecan—lung cancer	0.00187	0.00261	CcSEcCtD
Phentolamine—Bradycardia—Cisplatin—lung cancer	0.00187	0.0026	CcSEcCtD
Phentolamine—Acute coronary syndrome—Etoposide—lung cancer	0.00184	0.00257	CcSEcCtD
Phentolamine—Orthostatic hypotension—Docetaxel—lung cancer	0.00184	0.00256	CcSEcCtD
Phentolamine—Abdominal pain upper—Docetaxel—lung cancer	0.00184	0.00256	CcSEcCtD
Phentolamine—Hypertension—Vinorelbine—lung cancer	0.00184	0.00256	CcSEcCtD
Phentolamine—Myocardial infarction—Etoposide—lung cancer	0.00183	0.00255	CcSEcCtD
Phentolamine—Angiopathy—Irinotecan—lung cancer	0.00183	0.00255	CcSEcCtD
Phentolamine—Paraesthesia—Topotecan—lung cancer	0.00182	0.00254	CcSEcCtD
Phentolamine—Cardiac disorder—Gemcitabine—lung cancer	0.00182	0.00254	CcSEcCtD
Phentolamine—Mediastinal disorder—Irinotecan—lung cancer	0.00182	0.00253	CcSEcCtD
Phentolamine—Chest pain—Vinorelbine—lung cancer	0.00181	0.00253	CcSEcCtD
Phentolamine—Acute coronary syndrome—Paclitaxel—lung cancer	0.00181	0.00252	CcSEcCtD
Phentolamine—Arrhythmia—Irinotecan—lung cancer	0.0018	0.00251	CcSEcCtD
Phentolamine—Myocardial infarction—Paclitaxel—lung cancer	0.0018	0.0025	CcSEcCtD
Phentolamine—ADRA2A—trachea—lung cancer	0.00179	0.0239	CbGeAlD
Phentolamine—Pain—Vinblastine—lung cancer	0.00179	0.00249	CcSEcCtD
Phentolamine—Angiopathy—Gemcitabine—lung cancer	0.00178	0.00248	CcSEcCtD
Phentolamine—Mediastinal disorder—Gemcitabine—lung cancer	0.00177	0.00247	CcSEcCtD
Phentolamine—Arrhythmia—Gemcitabine—lung cancer	0.00176	0.00245	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Topotecan—lung cancer	0.00175	0.00244	CcSEcCtD
Phentolamine—Vomiting—Teniposide—lung cancer	0.00174	0.00243	CcSEcCtD
Phentolamine—Pain—Topotecan—lung cancer	0.00174	0.00242	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Erlotinib—lung cancer	0.00174	0.00242	CcSEcCtD
Phentolamine—Injection site reaction—Doxorubicin—lung cancer	0.00172	0.0024	CcSEcCtD
Phentolamine—Pain—Erlotinib—lung cancer	0.00172	0.00239	CcSEcCtD
Phentolamine—Headache—Teniposide—lung cancer	0.00172	0.00239	CcSEcCtD
Phentolamine—Gastrointestinal pain—Vinblastine—lung cancer	0.00171	0.00238	CcSEcCtD
Phentolamine—Nervous system disorder—Vinorelbine—lung cancer	0.0017	0.00237	CcSEcCtD
Phentolamine—Flushing—Cisplatin—lung cancer	0.0017	0.00237	CcSEcCtD
Phentolamine—Cardiac disorder—Cisplatin—lung cancer	0.0017	0.00237	CcSEcCtD
Phentolamine—Angina pectoris—Docetaxel—lung cancer	0.0017	0.00236	CcSEcCtD
Phentolamine—Tachycardia—Vinorelbine—lung cancer	0.0017	0.00236	CcSEcCtD
Phentolamine—ADRA2A—cardiac atrium—lung cancer	0.00168	0.0224	CbGeAlD
Phentolamine—Bradycardia—Paclitaxel—lung cancer	0.00168	0.00233	CcSEcCtD
Phentolamine—Gastrointestinal pain—Topotecan—lung cancer	0.00166	0.00231	CcSEcCtD
Phentolamine—Abdominal pain—Vinblastine—lung cancer	0.00165	0.0023	CcSEcCtD
Phentolamine—Mediastinal disorder—Cisplatin—lung cancer	0.00165	0.0023	CcSEcCtD
Phentolamine—Gastrointestinal pain—Erlotinib—lung cancer	0.00164	0.00229	CcSEcCtD
Phentolamine—Arrhythmia—Cisplatin—lung cancer	0.00164	0.00228	CcSEcCtD
Phentolamine—Nausea—Teniposide—lung cancer	0.00163	0.00227	CcSEcCtD
Phentolamine—Hypotension—Vinorelbine—lung cancer	0.00162	0.00226	CcSEcCtD
Phentolamine—ADRA2C—lung—lung cancer	0.00161	0.0215	CbGeAlD
Phentolamine—Abdominal pain—Topotecan—lung cancer	0.00161	0.00224	CcSEcCtD
Phentolamine—Abdominal pain—Erlotinib—lung cancer	0.00159	0.00221	CcSEcCtD
Phentolamine—Paraesthesia—Vinorelbine—lung cancer	0.00156	0.00217	CcSEcCtD
Phentolamine—Cardiac disorder—Etoposide—lung cancer	0.00156	0.00217	CcSEcCtD
Phentolamine—Flushing—Etoposide—lung cancer	0.00156	0.00217	CcSEcCtD
Phentolamine—Acute coronary syndrome—Docetaxel—lung cancer	0.00153	0.00213	CcSEcCtD
Phentolamine—Cardiac disorder—Paclitaxel—lung cancer	0.00153	0.00213	CcSEcCtD
Phentolamine—Flushing—Paclitaxel—lung cancer	0.00153	0.00213	CcSEcCtD
Phentolamine—Myocardial infarction—Docetaxel—lung cancer	0.00152	0.00212	CcSEcCtD
Phentolamine—Angiopathy—Etoposide—lung cancer	0.00152	0.00212	CcSEcCtD
Phentolamine—Hypertension—Irinotecan—lung cancer	0.00152	0.00211	CcSEcCtD
Phentolamine—Mediastinal disorder—Etoposide—lung cancer	0.00151	0.00211	CcSEcCtD
Phentolamine—Asthenia—Vinblastine—lung cancer	0.0015	0.00209	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Vinorelbine—lung cancer	0.0015	0.00209	CcSEcCtD
Phentolamine—Angiopathy—Paclitaxel—lung cancer	0.00149	0.00208	CcSEcCtD
Phentolamine—Pain—Vinorelbine—lung cancer	0.00149	0.00207	CcSEcCtD
Phentolamine—Mediastinal disorder—Paclitaxel—lung cancer	0.00148	0.00207	CcSEcCtD
Phentolamine—Hypertension—Gemcitabine—lung cancer	0.00148	0.00206	CcSEcCtD
Phentolamine—Arrhythmia—Paclitaxel—lung cancer	0.00147	0.00205	CcSEcCtD
Phentolamine—Asthenia—Topotecan—lung cancer	0.00146	0.00203	CcSEcCtD
Phentolamine—Chest pain—Gemcitabine—lung cancer	0.00146	0.00203	CcSEcCtD
Phentolamine—Asthenia—Erlotinib—lung cancer	0.00144	0.00201	CcSEcCtD
Phentolamine—Pruritus—Topotecan—lung cancer	0.00144	0.002	CcSEcCtD
Phentolamine—Diarrhoea—Vinblastine—lung cancer	0.00143	0.00199	CcSEcCtD
Phentolamine—Pruritus—Erlotinib—lung cancer	0.00142	0.00198	CcSEcCtD
Phentolamine—Gastrointestinal pain—Vinorelbine—lung cancer	0.00142	0.00198	CcSEcCtD
Phentolamine—Nervous system disorder—Irinotecan—lung cancer	0.00141	0.00196	CcSEcCtD
Phentolamine—SIGMAR1—lymph node—lung cancer	0.0014	0.0187	CbGeAlD
Phentolamine—Diarrhoea—Topotecan—lung cancer	0.00139	0.00194	CcSEcCtD
Phentolamine—Dizziness—Vinblastine—lung cancer	0.00138	0.00193	CcSEcCtD
Phentolamine—Diarrhoea—Erlotinib—lung cancer	0.00138	0.00192	CcSEcCtD
Phentolamine—Abdominal pain—Vinorelbine—lung cancer	0.00137	0.00191	CcSEcCtD
Phentolamine—Nervous system disorder—Gemcitabine—lung cancer	0.00137	0.00191	CcSEcCtD
Phentolamine—Dizziness—Topotecan—lung cancer	0.00134	0.00187	CcSEcCtD
Phentolamine—Hypotension—Irinotecan—lung cancer	0.00134	0.00187	CcSEcCtD
Phentolamine—Vomiting—Vinblastine—lung cancer	0.00133	0.00185	CcSEcCtD
Phentolamine—Dizziness—Erlotinib—lung cancer	0.00133	0.00185	CcSEcCtD
Phentolamine—Headache—Vinblastine—lung cancer	0.00131	0.00182	CcSEcCtD
Phentolamine—Hypotension—Gemcitabine—lung cancer	0.00131	0.00182	CcSEcCtD
Phentolamine—Cardiac disorder—Docetaxel—lung cancer	0.00129	0.0018	CcSEcCtD
Phentolamine—Flushing—Docetaxel—lung cancer	0.00129	0.0018	CcSEcCtD
Phentolamine—Vomiting—Topotecan—lung cancer	0.00129	0.0018	CcSEcCtD
Phentolamine—Paraesthesia—Irinotecan—lung cancer	0.00129	0.00179	CcSEcCtD
Phentolamine—ADRA2A—lung—lung cancer	0.00129	0.0172	CbGeAlD
Phentolamine—Vomiting—Erlotinib—lung cancer	0.00128	0.00178	CcSEcCtD
Phentolamine—Nervous system disorder—Cisplatin—lung cancer	0.00128	0.00178	CcSEcCtD
Phentolamine—Headache—Topotecan—lung cancer	0.00127	0.00177	CcSEcCtD
Phentolamine—Tachycardia—Cisplatin—lung cancer	0.00127	0.00177	CcSEcCtD
Phentolamine—Angiopathy—Docetaxel—lung cancer	0.00127	0.00176	CcSEcCtD
Phentolamine—Hypertension—Etoposide—lung cancer	0.00126	0.00176	CcSEcCtD
Phentolamine—Headache—Erlotinib—lung cancer	0.00126	0.00175	CcSEcCtD
Phentolamine—Mediastinal disorder—Docetaxel—lung cancer	0.00126	0.00175	CcSEcCtD
Phentolamine—Paraesthesia—Gemcitabine—lung cancer	0.00125	0.00175	CcSEcCtD
Phentolamine—Asthenia—Vinorelbine—lung cancer	0.00125	0.00174	CcSEcCtD
Phentolamine—Arrhythmia—Docetaxel—lung cancer	0.00125	0.00174	CcSEcCtD
Phentolamine—Chest pain—Etoposide—lung cancer	0.00124	0.00173	CcSEcCtD
Phentolamine—Nausea—Vinblastine—lung cancer	0.00124	0.00173	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Irinotecan—lung cancer	0.00124	0.00172	CcSEcCtD
Phentolamine—Hypertension—Paclitaxel—lung cancer	0.00124	0.00172	CcSEcCtD
Phentolamine—Pruritus—Vinorelbine—lung cancer	0.00123	0.00171	CcSEcCtD
Phentolamine—Pain—Irinotecan—lung cancer	0.00123	0.00171	CcSEcCtD
Phentolamine—Chest pain—Paclitaxel—lung cancer	0.00122	0.0017	CcSEcCtD
Phentolamine—Hypotension—Cisplatin—lung cancer	0.00122	0.00169	CcSEcCtD
Phentolamine—Nausea—Topotecan—lung cancer	0.00121	0.00168	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.00121	0.00168	CcSEcCtD
Phentolamine—Pain—Gemcitabine—lung cancer	0.00119	0.00166	CcSEcCtD
Phentolamine—Nausea—Erlotinib—lung cancer	0.00119	0.00166	CcSEcCtD
Phentolamine—Diarrhoea—Vinorelbine—lung cancer	0.00119	0.00166	CcSEcCtD
Phentolamine—Gastrointestinal pain—Irinotecan—lung cancer	0.00117	0.00163	CcSEcCtD
Phentolamine—Paraesthesia—Cisplatin—lung cancer	0.00117	0.00163	CcSEcCtD
Phentolamine—Tachycardia—Etoposide—lung cancer	0.00116	0.00162	CcSEcCtD
Phentolamine—Dizziness—Vinorelbine—lung cancer	0.00115	0.0016	CcSEcCtD
Phentolamine—Abdominal pain upper—Doxorubicin—lung cancer	0.00115	0.0016	CcSEcCtD
Phentolamine—Orthostatic hypotension—Doxorubicin—lung cancer	0.00115	0.0016	CcSEcCtD
Phentolamine—Nervous system disorder—Paclitaxel—lung cancer	0.00115	0.0016	CcSEcCtD
Phentolamine—Tachycardia—Paclitaxel—lung cancer	0.00114	0.00159	CcSEcCtD
Phentolamine—Abdominal pain—Irinotecan—lung cancer	0.00113	0.00158	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Cisplatin—lung cancer	0.00112	0.00157	CcSEcCtD
Phentolamine—Hypotension—Etoposide—lung cancer	0.00111	0.00155	CcSEcCtD
Phentolamine—Pain—Cisplatin—lung cancer	0.00111	0.00155	CcSEcCtD
Phentolamine—Vomiting—Vinorelbine—lung cancer	0.00111	0.00154	CcSEcCtD
Phentolamine—ADRA2C—lymph node—lung cancer	0.0011	0.0147	CbGeAlD
Phentolamine—Hypotension—Paclitaxel—lung cancer	0.00109	0.00152	CcSEcCtD
Phentolamine—Headache—Vinorelbine—lung cancer	0.00109	0.00152	CcSEcCtD
Phentolamine—Paraesthesia—Etoposide—lung cancer	0.00107	0.00149	CcSEcCtD
Phentolamine—Angina pectoris—Doxorubicin—lung cancer	0.00106	0.00148	CcSEcCtD
Phentolamine—Paraesthesia—Paclitaxel—lung cancer	0.00105	0.00146	CcSEcCtD
Phentolamine—Hypertension—Docetaxel—lung cancer	0.00105	0.00146	CcSEcCtD
Phentolamine—Chest pain—Docetaxel—lung cancer	0.00103	0.00144	CcSEcCtD
Phentolamine—Nausea—Vinorelbine—lung cancer	0.00103	0.00144	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Etoposide—lung cancer	0.00103	0.00143	CcSEcCtD
Phentolamine—Asthenia—Irinotecan—lung cancer	0.00103	0.00143	CcSEcCtD
Phentolamine—Pain—Etoposide—lung cancer	0.00102	0.00142	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.00101	0.00141	CcSEcCtD
Phentolamine—Asthenia—Gemcitabine—lung cancer	0.001	0.0014	CcSEcCtD
Phentolamine—Pain—Paclitaxel—lung cancer	0.001	0.00139	CcSEcCtD
Phentolamine—Pruritus—Gemcitabine—lung cancer	0.000988	0.00138	CcSEcCtD
Phentolamine—Diarrhoea—Irinotecan—lung cancer	0.000981	0.00137	CcSEcCtD
Phentolamine—Gastrointestinal pain—Etoposide—lung cancer	0.000975	0.00136	CcSEcCtD
Phentolamine—Nervous system disorder—Docetaxel—lung cancer	0.000972	0.00135	CcSEcCtD
Phentolamine—Tachycardia—Docetaxel—lung cancer	0.000967	0.00135	CcSEcCtD
Phentolamine—Gastrointestinal pain—Paclitaxel—lung cancer	0.000956	0.00133	CcSEcCtD
Phentolamine—Diarrhoea—Gemcitabine—lung cancer	0.000956	0.00133	CcSEcCtD
Phentolamine—Dizziness—Irinotecan—lung cancer	0.000948	0.00132	CcSEcCtD
Phentolamine—Abdominal pain—Etoposide—lung cancer	0.000943	0.00131	CcSEcCtD
Phentolamine—Asthenia—Cisplatin—lung cancer	0.000934	0.0013	CcSEcCtD
Phentolamine—Cardiac disorder—Methotrexate—lung cancer	0.000933	0.0013	CcSEcCtD
Phentolamine—Hypotension—Docetaxel—lung cancer	0.000926	0.00129	CcSEcCtD
Phentolamine—Abdominal pain—Paclitaxel—lung cancer	0.000924	0.00129	CcSEcCtD
Phentolamine—Angiopathy—Methotrexate—lung cancer	0.000912	0.00127	CcSEcCtD
Phentolamine—Vomiting—Irinotecan—lung cancer	0.000912	0.00127	CcSEcCtD
Phentolamine—Mediastinal disorder—Methotrexate—lung cancer	0.000906	0.00126	CcSEcCtD
Phentolamine—Headache—Irinotecan—lung cancer	0.000898	0.00125	CcSEcCtD
Phentolamine—Diarrhoea—Cisplatin—lung cancer	0.000891	0.00124	CcSEcCtD
Phentolamine—Paraesthesia—Docetaxel—lung cancer	0.00089	0.00124	CcSEcCtD
Phentolamine—Vomiting—Gemcitabine—lung cancer	0.000888	0.00124	CcSEcCtD
Phentolamine—Bradycardia—Doxorubicin—lung cancer	0.000886	0.00123	CcSEcCtD
Phentolamine—ADRA2A—lymph node—lung cancer	0.00088	0.0117	CbGeAlD
Phentolamine—Headache—Gemcitabine—lung cancer	0.000875	0.00122	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000856	0.00119	CcSEcCtD
Phentolamine—Asthenia—Etoposide—lung cancer	0.000856	0.00119	CcSEcCtD
Phentolamine—Nausea—Irinotecan—lung cancer	0.000852	0.00119	CcSEcCtD
Phentolamine—Pain—Docetaxel—lung cancer	0.000848	0.00118	CcSEcCtD
Phentolamine—Pruritus—Etoposide—lung cancer	0.000844	0.00117	CcSEcCtD
Phentolamine—Asthenia—Paclitaxel—lung cancer	0.000839	0.00117	CcSEcCtD
Phentolamine—Nausea—Gemcitabine—lung cancer	0.00083	0.00116	CcSEcCtD
Phentolamine—Vomiting—Cisplatin—lung cancer	0.000828	0.00115	CcSEcCtD
Phentolamine—Pruritus—Paclitaxel—lung cancer	0.000827	0.00115	CcSEcCtD
Phentolamine—Diarrhoea—Etoposide—lung cancer	0.000816	0.00114	CcSEcCtD
Phentolamine—Gastrointestinal pain—Docetaxel—lung cancer	0.00081	0.00113	CcSEcCtD
Phentolamine—Cardiac disorder—Doxorubicin—lung cancer	0.000808	0.00113	CcSEcCtD
Phentolamine—Flushing—Doxorubicin—lung cancer	0.000808	0.00113	CcSEcCtD
Phentolamine—Diarrhoea—Paclitaxel—lung cancer	0.0008	0.00111	CcSEcCtD
Phentolamine—Angiopathy—Doxorubicin—lung cancer	0.00079	0.0011	CcSEcCtD
Phentolamine—Dizziness—Etoposide—lung cancer	0.000789	0.0011	CcSEcCtD
Phentolamine—Mediastinal disorder—Doxorubicin—lung cancer	0.000785	0.00109	CcSEcCtD
Phentolamine—Abdominal pain—Docetaxel—lung cancer	0.000784	0.00109	CcSEcCtD
Phentolamine—Arrhythmia—Doxorubicin—lung cancer	0.000778	0.00108	CcSEcCtD
Phentolamine—Dizziness—Paclitaxel—lung cancer	0.000773	0.00108	CcSEcCtD
Phentolamine—Nausea—Cisplatin—lung cancer	0.000773	0.00108	CcSEcCtD
Phentolamine—Vomiting—Etoposide—lung cancer	0.000758	0.00106	CcSEcCtD
Phentolamine—Headache—Etoposide—lung cancer	0.000747	0.00104	CcSEcCtD
Phentolamine—Chest pain—Methotrexate—lung cancer	0.000745	0.00104	CcSEcCtD
Phentolamine—Vomiting—Paclitaxel—lung cancer	0.000743	0.00104	CcSEcCtD
Phentolamine—Headache—Paclitaxel—lung cancer	0.000733	0.00102	CcSEcCtD
Phentolamine—Asthenia—Docetaxel—lung cancer	0.000711	0.00099	CcSEcCtD
Phentolamine—Nausea—Etoposide—lung cancer	0.000708	0.000986	CcSEcCtD
Phentolamine—Pruritus—Docetaxel—lung cancer	0.000701	0.000976	CcSEcCtD
Phentolamine—Nervous system disorder—Methotrexate—lung cancer	0.000701	0.000976	CcSEcCtD
Phentolamine—Nausea—Paclitaxel—lung cancer	0.000695	0.000967	CcSEcCtD
Phentolamine—Diarrhoea—Docetaxel—lung cancer	0.000678	0.000944	CcSEcCtD
Phentolamine—Hypotension—Methotrexate—lung cancer	0.000668	0.00093	CcSEcCtD
Phentolamine—Dizziness—Docetaxel—lung cancer	0.000655	0.000913	CcSEcCtD
Phentolamine—Hypertension—Doxorubicin—lung cancer	0.000654	0.000911	CcSEcCtD
Phentolamine—Chest pain—Doxorubicin—lung cancer	0.000645	0.000899	CcSEcCtD
Phentolamine—Paraesthesia—Methotrexate—lung cancer	0.000641	0.000893	CcSEcCtD
Phentolamine—Vomiting—Docetaxel—lung cancer	0.00063	0.000878	CcSEcCtD
Phentolamine—Headache—Docetaxel—lung cancer	0.000621	0.000865	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000617	0.000859	CcSEcCtD
Phentolamine—Pain—Methotrexate—lung cancer	0.000611	0.000851	CcSEcCtD
Phentolamine—Nervous system disorder—Doxorubicin—lung cancer	0.000607	0.000845	CcSEcCtD
Phentolamine—Tachycardia—Doxorubicin—lung cancer	0.000604	0.000841	CcSEcCtD
Phentolamine—Nausea—Docetaxel—lung cancer	0.000589	0.00082	CcSEcCtD
Phentolamine—Gastrointestinal pain—Methotrexate—lung cancer	0.000584	0.000813	CcSEcCtD
Phentolamine—Hypotension—Doxorubicin—lung cancer	0.000578	0.000805	CcSEcCtD
Phentolamine—Abdominal pain—Methotrexate—lung cancer	0.000565	0.000786	CcSEcCtD
Phentolamine—Paraesthesia—Doxorubicin—lung cancer	0.000555	0.000773	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000534	0.000744	CcSEcCtD
Phentolamine—Pain—Doxorubicin—lung cancer	0.000529	0.000737	CcSEcCtD
Phentolamine—Asthenia—Methotrexate—lung cancer	0.000513	0.000714	CcSEcCtD
Phentolamine—Gastrointestinal pain—Doxorubicin—lung cancer	0.000506	0.000704	CcSEcCtD
Phentolamine—Pruritus—Methotrexate—lung cancer	0.000505	0.000704	CcSEcCtD
Phentolamine—Abdominal pain—Doxorubicin—lung cancer	0.000489	0.000681	CcSEcCtD
Phentolamine—Diarrhoea—Methotrexate—lung cancer	0.000489	0.000681	CcSEcCtD
Phentolamine—Dizziness—Methotrexate—lung cancer	0.000472	0.000658	CcSEcCtD
Phentolamine—Vomiting—Methotrexate—lung cancer	0.000454	0.000632	CcSEcCtD
Phentolamine—Headache—Methotrexate—lung cancer	0.000448	0.000623	CcSEcCtD
Phentolamine—Asthenia—Doxorubicin—lung cancer	0.000444	0.000618	CcSEcCtD
Phentolamine—Pruritus—Doxorubicin—lung cancer	0.000438	0.000609	CcSEcCtD
Phentolamine—Nausea—Methotrexate—lung cancer	0.000424	0.000591	CcSEcCtD
Phentolamine—Diarrhoea—Doxorubicin—lung cancer	0.000423	0.000589	CcSEcCtD
Phentolamine—Dizziness—Doxorubicin—lung cancer	0.000409	0.00057	CcSEcCtD
Phentolamine—Vomiting—Doxorubicin—lung cancer	0.000393	0.000548	CcSEcCtD
Phentolamine—Headache—Doxorubicin—lung cancer	0.000388	0.00054	CcSEcCtD
Phentolamine—Nausea—Doxorubicin—lung cancer	0.000367	0.000512	CcSEcCtD
Phentolamine—ADRA2B—Signaling by GPCR—KRAS—lung cancer	2.66e-05	0.000148	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—ERBB2—lung cancer	2.66e-05	0.000148	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3CB—lung cancer	2.64e-05	0.000147	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—AKT1—lung cancer	2.64e-05	0.000147	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL6R—lung cancer	2.64e-05	0.000147	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CREBBP—lung cancer	2.63e-05	0.000146	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—EGFR—lung cancer	2.63e-05	0.000146	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MTOR—lung cancer	2.62e-05	0.000146	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CB—lung cancer	2.62e-05	0.000146	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTGS2—lung cancer	2.62e-05	0.000146	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CREBBP—lung cancer	2.6e-05	0.000144	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—EGFR—lung cancer	2.59e-05	0.000144	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—APOA1—lung cancer	2.57e-05	0.000143	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MAP2K1—lung cancer	2.55e-05	0.000142	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KDR—lung cancer	2.54e-05	0.000141	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CD—lung cancer	2.54e-05	0.000141	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—KIT—lung cancer	2.52e-05	0.00014	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CG—lung cancer	2.52e-05	0.00014	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—APC—lung cancer	2.52e-05	0.00014	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—NRAS—lung cancer	2.52e-05	0.00014	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CXCL8—lung cancer	2.52e-05	0.00014	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MAP2K1—lung cancer	2.51e-05	0.00014	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—PIK3CA—lung cancer	2.51e-05	0.00014	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—HRAS—lung cancer	2.5e-05	0.000139	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CD—lung cancer	2.5e-05	0.000139	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGF—lung cancer	2.49e-05	0.000139	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—KRAS—lung cancer	2.48e-05	0.000138	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—PIK3CA—lung cancer	2.47e-05	0.000137	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CD—lung cancer	2.46e-05	0.000137	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—KRAS—lung cancer	2.44e-05	0.000136	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—PIK3CA—lung cancer	2.44e-05	0.000136	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—AKT1—lung cancer	2.43e-05	0.000135	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MDM2—lung cancer	2.43e-05	0.000135	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—ALB—lung cancer	2.43e-05	0.000135	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—RAF1—lung cancer	2.42e-05	0.000135	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—MAPK3—lung cancer	2.42e-05	0.000134	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CASP3—lung cancer	2.41e-05	0.000134	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL2—lung cancer	2.41e-05	0.000134	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—POMC—lung cancer	2.4e-05	0.000133	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ERBB2—lung cancer	2.4e-05	0.000133	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—IL6—lung cancer	2.4e-05	0.000133	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—BRAF—lung cancer	2.37e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MTOR—lung cancer	2.37e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CB—lung cancer	2.37e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCND1—lung cancer	2.35e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—APC—lung cancer	2.34e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KIT—lung cancer	2.34e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	2.34e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—NRAS—lung cancer	2.34e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL6R—lung cancer	2.34e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—JUN—lung cancer	2.34e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CREBBP—lung cancer	2.34e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGF—lung cancer	2.32e-05	0.000129	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—EGFR—lung cancer	2.3e-05	0.000128	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTEN—lung cancer	2.29e-05	0.000127	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—PIK3CA—lung cancer	2.28e-05	0.000127	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MMP9—lung cancer	2.28e-05	0.000127	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CXCL8—lung cancer	2.27e-05	0.000126	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MDM2—lung cancer	2.27e-05	0.000126	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CDKN1A—lung cancer	2.27e-05	0.000126	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PTEN—lung cancer	2.27e-05	0.000126	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—RAF1—lung cancer	2.26e-05	0.000126	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—HRAS—lung cancer	2.26e-05	0.000126	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—PIK3CA—lung cancer	2.25e-05	0.000125	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	2.24e-05	0.000125	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ERBB2—lung cancer	2.24e-05	0.000125	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MDM2—lung cancer	2.24e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MAP2K1—lung cancer	2.23e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—POMC—lung cancer	2.23e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—RAF1—lung cancer	2.23e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CD—lung cancer	2.22e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CB—lung cancer	2.21e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MTOR—lung cancer	2.21e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—AKT1—lung cancer	2.21e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ERBB2—lung cancer	2.21e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—BRAF—lung cancer	2.2e-05	0.000122	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—AKT1—lung cancer	2.2e-05	0.000122	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—PIK3CA—lung cancer	2.2e-05	0.000122	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—EP300—lung cancer	2.18e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CASP3—lung cancer	2.18e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL6R—lung cancer	2.18e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MTOR—lung cancer	2.18e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CB—lung cancer	2.18e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL2—lung cancer	2.17e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CREBBP—lung cancer	2.17e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—KRAS—lung cancer	2.17e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—IL6—lung cancer	2.16e-05	0.00012	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—EP300—lung cancer	2.16e-05	0.00012	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CB—lung cancer	2.15e-05	0.000119	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—EGFR—lung cancer	2.14e-05	0.000119	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTGS2—lung cancer	2.13e-05	0.000118	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CXCL8—lung cancer	2.12e-05	0.000118	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCND1—lung cancer	2.12e-05	0.000118	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—JUN—lung cancer	2.11e-05	0.000118	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—HRAS—lung cancer	2.11e-05	0.000117	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—SRC—lung cancer	2.1e-05	0.000117	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CXCL8—lung cancer	2.09e-05	0.000116	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—HRAS—lung cancer	2.08e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	2.07e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	2.06e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MMP9—lung cancer	2.06e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—AKT1—lung cancer	2.05e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CDKN1A—lung cancer	2.05e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—VEGFA—lung cancer	2.05e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PTEN—lung cancer	2.05e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	2.04e-05	0.000113	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CASP3—lung cancer	2.03e-05	0.000113	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL2—lung cancer	2.03e-05	0.000113	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—STAT3—lung cancer	2.03e-05	0.000113	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NRAS—lung cancer	2.02e-05	0.000112	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—IL6—lung cancer	2.02e-05	0.000112	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—AKT1—lung cancer	2.02e-05	0.000112	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—KRAS—lung cancer	2.02e-05	0.000112	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CASP3—lung cancer	2e-05	0.000111	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL2—lung cancer	2e-05	0.000111	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—AKT1—lung cancer	2e-05	0.000111	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	1.99e-05	0.000111	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—IL6—lung cancer	1.99e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MDM2—lung cancer	1.99e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—RAF1—lung cancer	1.98e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCND1—lung cancer	1.98e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—JUN—lung cancer	1.98e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ERBB2—lung cancer	1.96e-05	0.000109	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—EP300—lung cancer	1.95e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCND1—lung cancer	1.95e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—JUN—lung cancer	1.94e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MAPK3—lung cancer	1.94e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	1.93e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MTOR—lung cancer	1.93e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MMP9—lung cancer	1.92e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CDKN1A—lung cancer	1.92e-05	0.000106	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PTEN—lung cancer	1.91e-05	0.000106	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—SRC—lung cancer	1.9e-05	0.000105	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MMP9—lung cancer	1.89e-05	0.000105	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	1.88e-05	0.000105	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MYC—lung cancer	1.88e-05	0.000105	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PTEN—lung cancer	1.88e-05	0.000104	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—AKT1—lung cancer	1.86e-05	0.000104	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CXCL8—lung cancer	1.86e-05	0.000103	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTEN—lung cancer	1.86e-05	0.000103	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	1.85e-05	0.000103	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—VEGFA—lung cancer	1.85e-05	0.000103	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MDM2—lung cancer	1.85e-05	0.000103	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—HRAS—lung cancer	1.85e-05	0.000103	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—EGFR—lung cancer	1.84e-05	0.000102	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—RAF1—lung cancer	1.84e-05	0.000102	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—AKT1—lung cancer	1.83e-05	0.000102	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—STAT3—lung cancer	1.83e-05	0.000102	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NRAS—lung cancer	1.82e-05	0.000101	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—EP300—lung cancer	1.82e-05	0.000101	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	1.82e-05	0.000101	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	1.8e-05	9.98e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MTOR—lung cancer	1.8e-05	9.98e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	1.79e-05	9.97e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—EP300—lung cancer	1.79e-05	9.96e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CASP3—lung cancer	1.78e-05	9.88e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL2—lung cancer	1.78e-05	9.86e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SRC—lung cancer	1.77e-05	9.85e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—EP300—lung cancer	1.77e-05	9.84e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—IL6—lung cancer	1.77e-05	9.81e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MAPK3—lung cancer	1.75e-05	9.71e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SRC—lung cancer	1.74e-05	9.69e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—KRAS—lung cancer	1.74e-05	9.67e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCND1—lung cancer	1.73e-05	9.62e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—JUN—lung cancer	1.73e-05	9.6e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	1.73e-05	9.59e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—VEGFA—lung cancer	1.73e-05	9.59e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	1.71e-05	9.53e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—STAT3—lung cancer	1.71e-05	9.5e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NRAS—lung cancer	1.7e-05	9.47e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MYC—lung cancer	1.7e-05	9.45e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—VEGFA—lung cancer	1.7e-05	9.44e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—STAT3—lung cancer	1.68e-05	9.35e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MMP9—lung cancer	1.68e-05	9.34e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NRAS—lung cancer	1.68e-05	9.32e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	1.67e-05	9.3e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PTEN—lung cancer	1.67e-05	9.28e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	1.67e-05	9.26e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—EGFR—lung cancer	1.66e-05	9.24e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CASP3—lung cancer	1.65e-05	9.18e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL2—lung cancer	1.65e-05	9.17e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—IL6—lung cancer	1.64e-05	9.12e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MAPK3—lung cancer	1.63e-05	9.07e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—AKT1—lung cancer	1.63e-05	9.05e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3CA—lung cancer	1.61e-05	8.96e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCND1—lung cancer	1.61e-05	8.93e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MAPK3—lung cancer	1.61e-05	8.93e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—JUN—lung cancer	1.6e-05	8.92e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	1.6e-05	8.88e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EP300—lung cancer	1.59e-05	8.85e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MYC—lung cancer	1.59e-05	8.82e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—KRAS—lung cancer	1.57e-05	8.73e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MYC—lung cancer	1.56e-05	8.68e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MMP9—lung cancer	1.56e-05	8.67e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	1.56e-05	8.64e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—EGFR—lung cancer	1.55e-05	8.63e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PTEN—lung cancer	1.55e-05	8.62e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SRC—lung cancer	1.55e-05	8.61e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TP53—lung cancer	1.55e-05	8.59e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—EGFR—lung cancer	1.53e-05	8.49e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	1.51e-05	8.41e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—VEGFA—lung cancer	1.51e-05	8.38e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—STAT3—lung cancer	1.49e-05	8.3e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NRAS—lung cancer	1.49e-05	8.28e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EP300—lung cancer	1.48e-05	8.22e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—HRAS—lung cancer	1.48e-05	8.22e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—KRAS—lung cancer	1.47e-05	8.15e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—KRAS—lung cancer	1.44e-05	8.02e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	1.44e-05	8.02e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SRC—lung cancer	1.44e-05	8e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MAPK3—lung cancer	1.43e-05	7.93e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL6—lung cancer	1.42e-05	7.86e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	1.4e-05	7.79e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TP53—lung cancer	1.4e-05	7.76e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MYC—lung cancer	1.39e-05	7.71e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—STAT3—lung cancer	1.39e-05	7.71e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NRAS—lung cancer	1.38e-05	7.69e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGFR—lung cancer	1.36e-05	7.54e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	1.35e-05	7.49e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HRAS—lung cancer	1.34e-05	7.42e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	1.33e-05	7.37e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	1.33e-05	7.37e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AKT1—lung cancer	1.32e-05	7.32e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CA—lung cancer	1.31e-05	7.28e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AKT1—lung cancer	1.31e-05	7.26e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TP53—lung cancer	1.3e-05	7.25e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MYC—lung cancer	1.29e-05	7.17e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TP53—lung cancer	1.28e-05	7.13e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—KRAS—lung cancer	1.28e-05	7.13e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL6—lung cancer	1.28e-05	7.1e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGFR—lung cancer	1.26e-05	7.01e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HRAS—lung cancer	1.25e-05	6.93e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HRAS—lung cancer	1.23e-05	6.82e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL6—lung cancer	1.19e-05	6.63e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KRAS—lung cancer	1.19e-05	6.62e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AKT1—lung cancer	1.18e-05	6.55e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	1.18e-05	6.55e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL6—lung cancer	1.17e-05	6.53e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TP53—lung cancer	1.14e-05	6.33e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AKT1—lung cancer	1.1e-05	6.12e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	1.09e-05	6.08e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HRAS—lung cancer	1.09e-05	6.06e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKT1—lung cancer	1.08e-05	6.02e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AKT1—lung cancer	1.07e-05	5.94e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TP53—lung cancer	1.06e-05	5.89e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL6—lung cancer	1.04e-05	5.8e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HRAS—lung cancer	1.01e-05	5.63e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL6—lung cancer	9.7e-06	5.39e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT1—lung cancer	9.63e-06	5.35e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT1—lung cancer	8.94e-06	4.97e-05	CbGpPWpGaD
